Wegovy's heart benefits due to more than weight loss: Novo Nordisk - Video
|
Overview
Novo Nordisk presented groundbreaking data at the American Heart Association meeting, shedding light on the multifaceted cardiovascular benefits of its obesity treatment, Wegovy. Contrary to conventional understanding that the drug's efficacy is solely linked to weight loss, findings from the Select trial unveiled broader positive impacts on heart health.
Earlier data from the trial, released in August, had already shown that Wegovy, scientifically known as semaglutide, reduced the incidence of heart attacks, strokes, and death from heart disease by 20%, in addition to facilitating an average weight loss of 15% in patients.
For more news & updates, check out the link given below:
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
